The Caribbean island was represented by Cimab S.A. and for the foreign party Neuronic Mexicana S.A. de C.V., in the new entity with an exclusive license for the development and commercialization of innovative biotechnological products, including NeuroEPO, specified the first one on its Twitter account.
Considered one of the most promising assets in the portfolio of the Center for Molecular Immunology (CIM), a leading Cuban biotechnology company, NeuroEPO is an intranasal formulation of recombinant human erythropoietin with low sialic acid content, currently under clinical evaluation.
The latter studies the treatment of various neurodegenerative diseases such as Parkinson’s and Ataxia that, during the proof-of-concept trial recently completed in Cuba, showed evidence of acting as a homeostatic regulator of the brain and improvement of cognitive deterioration in Alzheimer’s patients.
Cimab S.A. is a company dedicated to the development and administration of businesses through its direct participation in international alliances that involve the main biotechnological products of the CIM.
With the incorporation of IncuBIO, that entity is a shareholder of five joint ventures located in China, Thailand, Singapore and in the national territory, the publication said.
Neuronic Mexicana S.A. de C.V., for its part, was established in 1996 and is dedicated to the commercialization of biopharmaceutical products and medical equipment.